Amicus Therapeutics, Inc (FOLD)

Etorro trading 970x250
Amicus Therapeutics, Inc (FOLD) Logo

About Amicus Therapeutics, Inc

Amicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering medicines for people living with rare metabolic diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant based on in vitro assay data; gene therapies for Fabry and Pompe diseases, as well as for various types of Batten diseases; enzyme replacement therapies for Pompe diseases; and CDKL5 deficiency disorder product candidates. The company also has additional gene therapies in active preclinical development, including gene therapies for mucopolysaccharidosis type IIIB, as well as a next generation program in mucopolysaccharidosis type IIIA. The company has collaboration and license agreements with Nationwide Children’s Hospital; University of Pennsylvania; and GlaxoSmithKline. Amicus Therapeutics, Inc. was incorporated in 2002 and is headquartered in Philadelphia, Pennsylvania. Address: 3675 Market Street, Philadelphia, PA, United States, 19104

Amicus Therapeutics, Inc News and around…

Latest news about Amicus Therapeutics, Inc (FOLD) common stock and company :

15 Biotech and Pharmaceutical Stocks to Buy According to Palo Alto Investors
23 Oct, 2021 Yahoo! Finance

In this article, we will take a look at 15 biotech and pharmaceutical stocks to buy according to Palo Alto Investors. You can skip our detailed analysis of the fund’s history, investment strategy, and hedge fund performance, and go directly to the 5 Biotech and Pharmaceutical Stocks to Buy According to Palo Alto Investors. Palo […]

Lifshitz Law Firm, P.C. Announces Investigation of FOLD, BCML, FIBK, and TGP
23 Oct, 2021 Yahoo! Finance

NEW YORK, NY / ACCESSWIRE / October 23, 2021 / Lifshitz Law Firm, P. (NasdaqGM:FOLD)Lifshitz Law Firm, P.

MERGER ALERT – DUNE, and FOLD: Levi & Korsinsky, LLP Reminds Investors of Investigations Concerning the Mergers of these Companies
19 Oct, 2021 Yahoo! Finance

NEW YORK, NY / ACCESSWIRE / October 19, 2021 / The following statement is being issued by Levi & Korsinsky, LLP:Levi & Korsinsky, LLP announces that investigations have commenced on behalf of shareholders of the following publicly-traded companies.Dune Acquisition Corporation (NASDAQ:DUNE)Agreement Announcement: October 12, 2021 Transaction Details:Upon the closing of the transaction, Dune will merge with TradeZero at a pro forma combined enterprise value of approximately $556 million and equity

Interesting FOLD Put And Call Options For December 17th
19 Oct, 2021 FinancialContent

Investors in Amicus Therapeutics Inc (FOLD) saw new options become available this week, for the December 17th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the FOLD options chain for the new December 17th contracts and identified one put and one call contract of particular interest.

Radius' (RDUS) Study on Tymlos for Osteoporosis in Men Meets Goal
19 Oct, 2021 Yahoo! Finance

Radius (RDUS) reports positive top-line results from the ATOM study evaluating Tymlos (abaloparatide) subcutaneous injection for use in men with osteoporosis. The study met the primary endpoint.

10 Best Biotech Stocks to Buy According to Joseph Edelman’s Perceptive Advisors
15 Oct, 2021 Yahoo! Finance

In this article, we will discuss the 10 best biotech stocks to buy according to Joseph Edelman’s Perceptive Advisors. If you want to skip our detailed analysis of Edelman’s history, investment philosophy, and hedge fund performance, go directly to the 5 Best Biotech Stocks to Buy According to Joseph Edelman’s Perceptive Advisors. Joseph Edelman, the […]

Is Amicus Therapeutics, Inc. (FOLD) A Good Stock To Buy?
12 Oct, 2021 Yahoo! Finance

After several tireless days we have finished crunching the numbers from nearly 900 13F filings issued by the elite hedge funds and other investment firms that we track at Insider Monkey, which disclosed those firms’ equity portfolios as of June 30th. The results of that effort will be put on display in this article, as […]

Wall Street Analysts Predict a 59% Upside in Amicus Therapeutics (FOLD): Here's What You Should Know
11 Oct, 2021 Yahoo! Finance

The average of price targets set by Wall Street analysts indicates a potential upside of 59.3% in Amicus Therapeutics (FOLD). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Notable Amicus Therapeutics Insider Trades $150K In Company Stock
05 Oct, 2021 Yahoo! Finance

Bradley Campbell, Chief Operating Officer at Amicus Therapeutics (NASDAQ:FOLD), made a large buy and sell of company shares on October 1, according to a new SEC filing. What Happened: A Form 4 filing from the U.S. Securities and Exchange Commission states that Bradley Campbell exercised options to purchase 10,515 Amicus Therapeutics shares at a price of $4.38 per share for a total of $46,056 on October 1. They then sold their shares on the same day in the open market. They sold at a price of $10

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation into the Fairness of the Merger of Amicus Therapeutics, Inc. with ARYA Sciences Acquisition Corp IV
04 Oct, 2021 Yahoo! Finance

New York, New York--(Newsfile Corp. - October 4, 2021) - The following statement is being issued by Levi & Korsinsky, LLP:To: All Persons or Entities who purchased Amicus Therapeutics, Inc. (NASDAQ: FOLD) ("Amicus" or the "Company") stock prior to September 29, 2021.You are hereby notified that Levi & Korsinsky, LLP has commenced an investigation into the fairness of the merger of Amicus with ARYA Sciences Acquisition Corp IV. Upon the closing of the ...

The Week In SPAC News - Sunday, Oct. 3
03 Oct, 2021 FinancialContent

In SPAC news this week, Amicus Therapeutics announced its intent to sell its gene therapy unit to ARYA Sciences Acquisition Corp IV, a SPAC sponsored by Perceptive Advisors.

Amcius (FOLD) to Spin-Off Gene Therapy Arm, Form New Firm With ARYA
30 Sep, 2021 Yahoo! Finance

Amicus (FOLD) plans to separate its gene therapy business into a new company formed in alliance with ARYA Sciences Acquisition Corp.

Benzinga's Top Ratings Upgrades, Downgrades For September 30, 2021
30 Sep, 2021 FinancialContent

Upgrades For Cabot Oil & Gas Corp (NYSE:COG), Wolfe Research upgraded the previous rating of Peer Perform to Outperform. For the ...

Amicus stock is up 5%, the day after announcing plans to sell its gene therapy business
30 Sep, 2021 Yahoo! Finance

Shares of Amicus Therapeutics Inc. were up 5.6% in premarket trading on Thursday, the day after the company announced a deal to sell its gene therapy business to ARYA Sciences Acquisition Corp IV , a special purpose acquisition company sponsored by Perceptive Advisors. Amicus will have a 36% stake in the new company, which will be called Caritas Therapeutics Inc. It will retain commercialization rights to the Fabry and Pompe gene therapy programs. Amicus chair and CEO John Crowley will become ch

Amicus Therapeutics Stock Rises; Sells Unit Stake in SPAC Deal
30 Sep, 2021 Yahoo! Finance

Amicus is selling a stake in its gene-therapy unit to ARYA Sciences Acquisition IV, a special purpose acquisition company sponsored by Perceptive Advisors.

SHAREHOLDER NOTICE: Brodsky & Smith Announces an Investigation of ARYA Sciences Acquisition Corp IV (Nasdaq - ARYD)
29 Sep, 2021 Yahoo! Finance

("Amicus") (NASDAQ:FOLD), and result in Amicus' gene therapy business becoming Caritas Therapeutics, Inc., ("Caritas"), which will be a publicly-listed company.

Perceptive Advisors-Backed SPAC To Acquire Amicus's Gene Therapy Business
29 Sep, 2021 FinancialContent

Amicus Therapeutics Inc(NASDAQ: FOLD) hasagreed to spin off its gene therapy businesstoSciences Acquisition ...

Why Are Amicus Therapeutics Shares Trading Higher Today?
29 Sep, 2021 FinancialContent

TheFDA has accepted for reviewAmicus Therapeutics Inc's(NASDAQ: FOLD) Biologics License Application (BLA) for ...

The Daily Biotech Pulse: AbbVie's Migraine Drug OK'd By FDA, Amicus Spins Off Gene Therapy Business, Geovax In-Licenses Cancer Drug
29 Sep, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours. Click here for accessing Benzinga's FDA ...

12 Health Care Stocks Moving In Wednesday's Pre-Market Session
29 Sep, 2021 FinancialContent

Gainers Geovax Labs (NASDAQ:GOVX) shares increased by 23.44% to $5.16 during Wednesday's pre-market session. The ...

Amicus Therapeutics and ARYA Sciences Acquisition Corp IV Announce Formation of a Next-Generation Genetic Medicine Company: “Caritas Therapeutics”
29 Sep, 2021 FinancialContent
U.S. FDA Accepts Filings for Amicus’ AT-GAA for the Treatment of Pompe Disease
29 Sep, 2021 FinancialContent
IHE's Underlying Holdings Could Mean 23% Gain Potential
27 Sep, 2021 FinancialContent

Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the iShares US.

Amicus Therapeutics Announces Presentations at the 26th International Annual Congress of the World Muscle Society
20 Sep, 2021 FinancialContent
Those who invested in Amicus Therapeutics (NASDAQ:FOLD) five years ago are up 43%
16 Sep, 2021 Yahoo! Finance

When you buy and hold a stock for the long term, you definitely want it to provide a positive return. Better yet, you'd...

First Week of FOLD January 2024 Options Trading
14 Sep, 2021 FinancialContent

Investors in Amicus Therapeutics Inc (FOLD) saw new options become available this week, for the January 2024 expiration. One of the key data points that goes into the price an option buyer is willing to pay, is the time value, so with 857 days until expiration the newly available contracts represent a potential opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration..

12 Health Care Stocks Moving In Tuesday's After-Market Session
07 Sep, 2021 FinancialContent

Gainers Cellectar Biosciences (NASDAQ:CLRB) shares increased by 3.84% to $1.08 during Tuesday's after-market session. This security ...

Amicus Therapeutics to Present at Upcoming Investor Conferences in September 2021
03 Sep, 2021 FinancialContent
IHE's Underlying Holdings Could Mean 16% Gain Potential
25 Aug, 2021 FinancialContent

Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the iShares US.

Is It Time to Buy 5 of the Nasdaq's Worst-Performing Stocks of 2021?
12 Aug, 2021 FinancialContent

One particular group of stocks is overrepresented among the exchange's biggest losers this year. That's an important detail.

Amicus Therapeutics, Inc (FOLD) is a NASDAQ Common Stock listed in , ,

970x250